Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.
- EligibilityCriteria: Inclusion Criteria:  Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma >= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting Platinum-free interval should be >=6 months from the last dose of platinum-based chemotherapy Upfront SCR not feasible Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment. Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.  Exclusion Criteria:  Non-epithelial or borderline tumors are excluded Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded. Patients using more than one line of chemotherapy are excluded. Patients who have platinum-resistant or refractory recurrence are excluded. Patients having second relapse or beyond are excluded. Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment - HealthyVolunteers: No - Gender: Female - GenderBased: Yes - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult